Pharma Grade
At the higher loading typical of drug-product formulation, guar gum's hydrophilic gel layer becomes robust and predictable enough to serve as a sustained-release matrix, a wet-granulation binder, or a suspending agent for liquid oral dosage forms.
Overview
Pharma Grade (GG-PHA) is developed specifically for pharmaceutical formulators working within the drug-product regulatory pathway — a different qualification route from the nutraceutical and dietary supplement category that GG-NUT serves. That difference shows up directly in the dosage range: GG-PHA's typical loading of 2–10% is meaningfully higher than GG-NUT's 0.5–5%, because the functional role shifts at that level. At lower dosage, guar gum's swelling behavior gives a tablet either fast disintegration or a modest gel layer; at the higher loading typical of this grade's applications, that same hydrophilic gel layer becomes robust and predictable enough to serve as the primary matrix controlling drug release over an extended period — the basis for sustained-release tablet formulation. The same viscosity-building property extends to liquid oral dosage forms, where guar gum keeps poorly soluble active ingredients suspended and re-dispersible after settling, and to ophthalmic formulations, where a documented history of use as a gelling agent in artificial tears extends contact time on the ocular surface. Typical dosage ranges from 2–10%, adjustable to your specific dosage form and release profile target.
Key Benefits
USP/EP Compliant
Manufactured and tested to United States Pharmacopeia / European Pharmacopoeia monograph specifications.
Controlled Release
Forms a hydrophilic gel matrix that regulates drug diffusion rate for sustained or controlled-release dosage forms.
Tablet Disintegrant
Swells rapidly on contact with fluid to break tablets apart quickly and reliably for consistent dissolution.
Sustained-Release Matrix Formation
At the 2–10% loading typical of this grade, guar gum's hydrophilic gel layer becomes robust and predictable enough to serve as the primary matrix controlling drug release over an extended period, rather than the faster, more modest gel layer seen at lower dosage.
Oral Suspension Viscosity & Resuspendability
Keeps poorly soluble active ingredients suspended in liquid oral dosage forms, and — because settling during shelf storage is unavoidable in most suspensions — re-disperses reliably with a reasonable shake, which matters most for pediatric and geriatric formulations where vigorous shaking isn't always reliably performed.
Ophthalmic Formulation Compatibility
Has a documented history of use as a gelling and viscosity-building agent in artificial tear and ophthalmic lubricant formulations, where it extends the formulation's contact time on the ocular surface.
Wet Granulation Binder Strength
Provides cohesive granule strength in wet granulation processes at pharmaceutical production scale, supporting consistent tablet hardness across the higher excipient loading this grade is formulated for.
Elemental Impurity & DMF Documentation
Ships with documentation aligned to drug-product regulatory requirements — including elemental impurity data suited to ICH Q3D risk assessment and DMF Type IV reference information — a deeper documentation package than dietary supplement qualification typically requires.
Technical Specifications
| Product Code | GG-PHA |
| Category | Pharma & Nutra |
| Recommended Dosage | 2–10% |
| Primary Application | Sustained-release tablets, Wet-granulated tablets, Capsule matrix formulations, Oral suspensions, Pediatric liquid formulations, Ophthalmic lubricant formulations, Prescription topical gels |
Formulation Guidance
Matrix erosion rate in sustained-release formulations is tunable through both guar gum percentage and particle size, and the two interact — finer particle size combined with higher percentage compounds the rate of gel-layer formation, which can slow release further than either variable would alone. Confirm both together during early formulation trials rather than optimizing one and then the other.
In wet granulation, guar gum's binder strength is sensitive to granulation liquid volume and drying conditions. It's worth establishing a granulation end-point (via torque or power-consumption monitoring, for example) specific to guar-gum-bound formulations rather than porting over an end-point calibrated for a different binder system, since optimal moisture content at the end-point isn't necessarily the same across binder types.
For oral suspensions, confirm resuspension force against your target patient population's realistic shake behavior — a suspension that resuspends easily in a lab shake test may not perform the same way for a patient population that shakes less vigorously or less consistently.
Because drug-product formulations carry a deeper regulatory documentation requirement than nutraceutical qualification, request elemental impurity data aligned with ICH Q3D risk assessment alongside the standard Certificate of Analysis and DMF Type IV reference — dietary supplement qualification typically doesn't require this same depth of documentation, so it's worth confirming this is available before scale-up.
Ready to Trial Pharma Grade?
Our technical team can help with dosage guidance and formulation support.